More than 300 million people worldwide live with depression, but if you asked any two of them to describe their experience with it, you'd get two different answers, which makes depression incredibly hard to treat.
Therapy alone can help some people, but others require medication, and while there are dozens of approved antidepressants on the market, a drug that helps one person might not do anything for another — and it might even make their symptoms worse.
Subscribe to Freethink for more stories like this.
Now, a new study suggests that a single type of treatment might be able to help as many as half of all people with major depression disorder.
Psilocybin Therapy for Depression
The study, published in the journal JAMA Psychiatry, comes out of the Johns Hopkins Center for Psychedelic Research, which is a leading investigator into whether psychedelic drugs can have therapeutic uses.
Johns Hopkins researchers had previously reported that psilocybin therapy decreased depression symptoms in people with life-threatening cancer, and for the new study, they aimed to find out whether it could help the general population, too.
They enrolled 24 participants in the study. Each had a documented history of depression and none were taking antidepressants (if they had been on them at the time of enrollment, they had to taper off before starting the psilocybin therapy).
"We really encourage them to go inward."
The participants underwent two five-hour sessions, during which they received a dose of psilocybin and basically chilled out under the researchers' supervision.
"They have a blindfold on, they have headphones on, listening to music," researcher Alan Davis told NPR. "And we really encourage them to go inward and to kind of experience whatever is going to come up with the psilocybin."
These sessions happened two weeks apart from one another. The participants also received about 11 hours each of supportive psychotherapy without any drugs.
Fast-Acting Depression Treatment
Each participant completed a standard depression assessment survey when they enrolled in the study and then twice more, one and four weeks later, after completing the psilocybin therapy.
At the beginning, the average score was 23 (24 and up indicates severe depression, while 7 or less indicates no depression). During the follow-up surveys, the average score was 8, and more than half of the participants no longer qualified as having depression.
"The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market," Davis said in a news release.
"This could be a game changer if these findings hold up in future trials."
Though the results were promising, the study did have several limitations.
The sample size was small and did not include a control arm — all of the participants received the psilocybin therapy. Additionally, the researchers only followed up with the participants for four weeks, and the impact of the therapy could wane with time.
However, they do plan to continue to follow up with the participants for at least a year and share those results in the future. For now, they believe their study shows that psilocybin therapy warrants additional research as a depression treatment.
"Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future 'gold-standard' placebo-controlled clinical trials," Davis said.
We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].